Reference : Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteopor...
Scientific journals : Article
Human health sciences : Rheumatology
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Adami, S. [> > > >]
Lakatos, P. [> > > >]
Greenwald, M. [> > > >]
Stepan, J. J. [> > > >]
Silverman, S. L. [> > > >]
Christiansen, C. [> > > >]
Rowell, L. [> > > >]
Mairon, N. [> > > >]
Bonvoisin, B. [> > > >]
Drezner, M. K. [> > > >]
Emkey, R. [> > > >]
Felsenberg, D. [> > > >]
Cooper, C. [> > > >]
Delmas, P. D. [> > > >]
Miller, P. D. [> > > >]
Annals of the Rheumatic Diseases
B M J Publishing Group
Yes (verified by ORBi)
[en] BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE: To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis. METHODS: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral fracture risk in comparison with placebo. RESULTS: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better (p<0.001). Substantial increases in proximal femur (total hip, femoral neck, trochanter) BMD were seen; 150 mg produced the most pronounced effect (p<0.05 versus daily treatment). Independent of the regimen, most participants (70.5-93.5%) achieved increases above baseline in lumbar spine or total hip BMD, or both. Pronounced decreases in the biochemical marker of bone resorption, sCTX, observed in all arms after 3 months, were maintained throughout. The 150 mg regimen consistently produced greater increases in BMD and sCTX suppression than the 100 mg and daily regimens. Ibandronate was well tolerated, with a similar incidence of adverse events across groups. CONCLUSIONS: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment. Once-monthly administration may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes.

File(s) associated to this reference

Fulltext file(s):

Open access
efficacy and tolerability....pdfPublisher postprint286.56 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.